SMARCA4 mutations drive metastatic progression and predict poor survival in breast cancer based on a real-world cohort study.
Saved in:
| Title: | SMARCA4 mutations drive metastatic progression and predict poor survival in breast cancer based on a real-world cohort study. |
|---|---|
| Authors: | Yang Y; Second Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China., Guo Y; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China., Zhu M; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China., Dong Z; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China., Jiang S; The Second People's Hospital of Hunan Province, Brain Hospital of Hunan Province, Hunan, China., Wen X; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China., Jiang Z; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China. zhjiang@tmu.edu.cn. |
| Source: | Discover oncology [Discov Oncol] 2026 May 05; Vol. 17 (1). Date of Electronic Publication: 2026 May 05. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 101775142 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-6011 (Electronic) Linking ISSN: 27306011 NLM ISO Abbreviation: Discov Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2730-6011 |
|---|---|
| DOI: | 10.1007/s12672-026-05110-0 |
